Table 2.
Adherence levels among PWID in LMIC ART programs
| Study | Country | Study Year | Adherence Category (1–3)* | Months of Follow-up | Country | ART Regimen | PWID (n) | Adherence (%) |
|---|---|---|---|---|---|---|---|---|
| Campos 2010 (25) | Brazil | 2001–2002 | 2 | 12 | Brazil | NRTI Protease Inhibitor Ritonavir |
17 | 35.3 |
| Malta 2009 (49) | Brazil | 2000–2006 | 1 | 72 | Brazil | [HAART]: Not specified | 12231 | 33.1 |
| Melo 2006 (20) | Brazil | 1996–2002 | 1 | 84 | Brazil | [HAART]: Not specified | 67 | 38.9 |
| DeSilva 2013 (21) | China | 2012 | 3 | 1 | China | [HAART]: Not specified | 10 | 97.2 |
| Ma 2010 (22) | China | 2007–2008 | 3 | 12 | China | [HAART]: Not specified | 180 | 70.6 |
| Wang 2008 (26) | China | 2006 | 2 | 4 | China | Zidovudine, Stavudine Didanosine, Lamivudine Nevirapine, Efavirenz |
25 | 56 |
| Zhao 2013 (27) | China | 2011 | 3 | 6 | China | Zidovudine, Lamivudine Nevirapine, Efavirenz |
3642 | 67.5 |
| Zhao 2013 (27) | China | 2011 | 3 | 6 | China | Zidovudine, Lamivudine Nevirapine, Efavirenz |
932 | 72.3 |
| Uuskula 2012 (23) | Estonia | 2010 | 2 | 6 | Estonia | [HAART]: Not specified | 144 | 87.5 |
| Sharma 2007 (50) | India | 2004–2005 | 3 | 5 | India | Stavudine, Lamivudine Zidovudine, Nevirapine Efavirenz |
226 | 67.2 |
| Wisaksana 2010 (28) | Indonesia | 1996–2008 | 2 | 148 | Indonesia | Neviprapine, Efavirenz Zidovudine, Stavudine Lamivudine |
530 | 87.2 |
| Shaboltas 2013 (29) | Russia | 2007–2008 | 3 | 8 | Russia | Didanosine, Lamivudine Zidovudine, Nevirapine Lopinavir |
60 | 88.3 |
| Amirkhanian 2011 (51) | Russia | 2008–2009 | 2 | 12 | Russia | [HAART]: Not specified | 312 | 94.1 |
| Burdon 2006 (24) | Vietnam | 2005 | 2 | 2 | Vietnam | [HAART]: Not specified | 300 | 92.3 |
| Jordan 2009 (52) | Vietnam | 2006 | 3 | 1 | Vietnam | Didanosine, Lamivudine Zidovudine, Nevirapine Lopinavir, Nelfinavir Abacavir, Stavudine |
91 | 96.3 |
| Nguyen 2013 (53) | Vietnam | 2008–2009 | 1 | 48 | Vietnam | Tenofovir Lamivudine Efavirenz |
2491 | 63.3 |
*
See Table 1 for breakdown of the different ART adherence measurement categories